ReviewFrontiers in immunology2021
Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 3 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- IL-23 serum levels and IL23R polymorphisms in psoriasis: a meta-analysis of susceptibility and severity.BMC immunology · 2026Pooled it
- Short-term efficacy of biologics targeting the IL-17/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Efficacy and safety of mirikizumab in psoriasis: a systematic review and meta-analysis of randomized controlled trials.Inflammopharmacology · 2025Pooled it
- Large-scale comparative virtual screening identifies novel molecular targets underlying the multi-target activity of quercetin in psoriasis.Inflammopharmacology · 2026Article
- Transcriptomic Insights into Acupuncture Mechanisms in Protecting Ovarian Function in Mice with Premature Ovarian Insufficiency.Chinese journal of integrative medicine · 2026Article
- Pink lotus flower (Biomedical reports · 2026Article
- Depletion of p75NTR in Schwann Cells Driven by Inflammation Mediates Cutaneous Pain in Psoriasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- γδ T Cell-Mediated Neuroimmune Interactions in Skin Inflammation and Allergy.Clinical reviews in allergy & immunology · 2026Review
- Dissecting the role of imiquimod and isostearic acid in Aldara-induced psoriasis mouse model.JID innovations : skin science from molecules to population health · 2026Article
- Wogonin attenuates psoriasis through anti-inflammatory effects by inhibiting reactive oxygen species production and the AKT/NF-κB signaling pathway.Scientific reports · 2026Article
- Biomarkers for diagnosis, disease progression, and therapeutic response in psoriasis vulgaris: A mini-review.Narra J · 2026Review
- Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities.Inflammopharmacology · 2026Review
- Effects of Overload on Imiquimod-Induced Psoriasis Model Mice: A Basic Experimental Study.Health science reports · 2026Article
- Mucosal-Associated Invariant T (MAIT) Cells in Skin Immunity: Metabolic Regulation, Tissue Adaptation, and Roles in Skin Inflammation and Disease.JID innovations : skin science from molecules to population health · 2026Review
- T helper 17 cells and group 3 innate lymphoid cells define a spectrum of psoriasis endotypes.Frontiers in immunology · 2026Review
- From apremilast to JAK inhibitors-salvage treatment strategies for refractory palmoplantar pustulosis: case series.Frontiers in medicine · 2026Article
- Exploring the Role of Phytoconstituent FromFood science & nutrition · 2025Article
- Low molecular weight sulfated galactan attenuates imiquimod-induced psoriasis via suppression of proinflammatory cytokines and keratinocyte hyperproliferation.Biomedical reports · 2025Article
- Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Screening of key genes related to disulfidptosis in psoriasis based on the analysis of WGCNA.Scientific reports · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a frequent, chronic disease characterized by cutaneous inflammatory plaques and/or arthritis. It may be associated with few other diseases, mainly Crohn's disease and metabolic syndrome. The medical and psychosocial burden of psoriasis remains high even since biological treatments arose, stressing that efforts to decipher its physiopathology are constantly needed. Tumor-necrosis factor α, interleukin (IL) 12 and IL17 have been previously associated with psoriasis and successfully targeted by monoclonal antibodies. IL17 in particular has been initially described as a T helper (Th) 17-produced cytokine, but it is now established that other cell types, such as γδ T lymphocytes, Mucosal-Associated Invariant T (MAIT) cells and Innate Lymphoïd Cells (ILC) 3 are also important sources of IL17 in the skin in response to inflammatory stimuli. Th17 phenotype has been shown to be stabilized by IL23, which is synthetized by macrophages and dendritic cells in response to Toll Like Receptors and C-type Lectin Receptors stimulation. Recent data also reported a crucial role for IL23 in MAIT17 and ILC3 homeostasis. Genome-wide association studies have found a significant link between IL23 receptor polymorphism and psoriasis susceptibility. IL23 signals through Janus kinase 2 and Tyrosine kinase 2, against which specific inhibitors are currently being tested. Monoclonal antibodies against IL17 and IL23 are only the beginning of a new avenue in psoriasis treatment. This review focuses on the molecular basis underlying IL23/IL17 axis blockade in psoriasis, and on future targets in this pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.